CMAX Clinical Research
Adelaide (Kaurna), South Australia.
Australian Export Awards celebrates Australia's role in advancing global health
Being recognised as the 2025 winner of the Professional Services award is a proud recognition of our team’s dedication and a powerful endorsement of our global growth strategy.
Jane Kelly, Chief Executive Officer.
CMAX Clinical Research: High-quality healthcare starts here
For 31 years, CMAX Clinical Research has delivered Aussie efficacy to the global pharmaceutical and biotech industries.
Leveraging Australia’s efficient research approval process, the independent clinical trial facility and winner of the 2025 Professional Services award category, delivers fast results to the highest safety and quality standards.
Its services are in huge demand, especially from the US and Asia where trial approval timelines are typically slower.
Since 1993, CMAX has delivered more than 800 early-phase clinical trials, including over 200 first-time-in-human studies.
Export sales on the rise
In the past year, CMAX has achieved remarkable international growth, with export sales rising across key global markets.
Exports to the US rose by 44%, China by 86% and South Korea by 7%. In Europe, a whopping 570% increase from the previous financial year has driven further expansion.
‘These gains reflect the success of our targeted market strategies, improved brand positioning, and greater direct-to-client engagement with global biotechs and pharma sponsors,’ says Jane Kelly, Chief Executive Officer at CMAX Clinical Research.
Reputation and trust as the foundations of global growth
Australia’s scientific rigour, efficient regulatory processes, and high-quality healthcare give CMAX an advantage in exporting world-class clinical trials.
‘Competition for clinical trial sites is strong globally and within Australia. We are addressing this by emphasising our speed, quality and expertise,’ says Kelly.
‘We believe reputation and trust are the true foundations of global growth.’
CMAX expansion crosses continents
South Korea has recently become a key market for CMAX.
‘While we always saw potential there, the rapid growth in demand for early-phase clinical research has exceeded our expectations,’ says Kelly. ‘Our investment in local conferences and relationships has helped us establish a presence quickly.’
The company’s next target market is Europe, a key growth region with strong biotech activity. ‘This expansion supports our goal of delivering high-quality Australian clinical expertise to more global partners,’ says Kelly.
The future is digital
A recent make-or-break moment for CMAX was embracing digital transformation across its operations.
‘We’ve implemented e-Source, a participant portal, e-screening, e-consent, and other digital initiatives,’ says Kelly. ‘This has strengthened our resilience, improved efficiency, and modernised our clinical trial capabilities.’
These initiatives reflect CMAX’s broader values of transparency, sustainability, ethical practice and social impact. These values are resonating strongly with its international clients.
Austrade’s support in facilitating introductions, providing market insights, and promoting Australian clinical research expertise has accelerated our global growth.
Australian Export Awards celebrates Australia’s role in advancing global health
This is CMAX’s third recognition in the Australian Export Awards. It won the Professional Services award category in 2021 and was a 2018 finalist in the Business Services award category.
‘We applied to highlight Australia’s important role in advancing global health through world-class clinical research,’ says Kelly.
‘Being recognised as the 2025 winner of the Professional Services award is a proud recognition of our team’s dedication and a powerful endorsement of our global growth strategy.’
Austrade facilitates meaningful connections
Kelly notes that Austrade has been invaluable in connecting CMAX with partners across the US, Asia, Europe and beyond.
This has strengthened the company’s foothold in critical export markets.
‘Austrade’s support in facilitating introductions, providing market insights, and promoting Australian clinical research expertise has accelerated our global growth,’ says Kelly.
A legacy in global healthcare
After more than 3 decades, CMAX continues to forge strong working relationships with medical experts. This enables clinical trials to be delivered across a wide variety of therapeutic areas.
‘Our legacy will be helping bring new medicines to patients faster through world-class clinical trials,’ says Kelly.
‘Making a real difference in patient lives and advancing tomorrow’s healthcare is what drives everything we do.’
Visit CMAX Clinical Research website.
